Dr. Patrick J. Hensley shares the treatment landscape of non-muscle-invasive bladder, as well as how individual risk factors can alter treatment options. Non-muscle-invasive bladder cancer remains a ...

NMIBC treatment varies by tumor stage, grade, and prior therapies, with high-risk cases often requiring radical cystectomy. Bladder-preserving approaches include intravesical therapies like BCG, ...

While the current approval focuses on the second-line setting, research is already moving into earlier stages of the disease.The ongoing SunRISe-3 trial (NCT05714202) is testing TAR-200 head-to-head ...

Patients with early bladder cancer who have gone 5 years without relapse may be considered “cured,” researchers suggested. In considering outcomes for evaluating how “cure” is defined in early bladder ...